636 related articles for article (PubMed ID: 9563506)
1. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
Derocq JM; Bouaboula M; Marchand J; Rinaldi-Carmona M; Ségui M; Casellas P
FEBS Lett; 1998 Apr; 425(3):419-25. PubMed ID: 9563506
[TBL] [Abstract][Full Text] [Related]
2. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells.
Sugiura T; Kondo S; Kishimoto S; Miyashita T; Nakane S; Kodaka T; Suhara Y; Takayama H; Waku K
J Biol Chem; 2000 Jan; 275(1):605-12. PubMed ID: 10617657
[TBL] [Abstract][Full Text] [Related]
3. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions.
Bouaboula M; Perrachon S; Milligan L; Canat X; Rinaldi-Carmona M; Portier M; Barth F; Calandra B; Pecceu F; Lupker J; Maffrand JP; Le Fur G; Casellas P
J Biol Chem; 1997 Aug; 272(35):22330-9. PubMed ID: 9268384
[TBL] [Abstract][Full Text] [Related]
4. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1.
Bouaboula M; Poinot-Chazel C; Bourrié B; Canat X; Calandra B; Rinaldi-Carmona M; Le Fur G; Casellas P
Biochem J; 1995 Dec; 312 ( Pt 2)(Pt 2):637-41. PubMed ID: 8526880
[TBL] [Abstract][Full Text] [Related]
5. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures.
Molina-Holgado F; Molina-Holgado E; Guaza C; Rothwell NJ
J Neurosci Res; 2002 Mar; 67(6):829-36. PubMed ID: 11891798
[TBL] [Abstract][Full Text] [Related]
6. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction.
Felder CC; Briley EM; Axelrod J; Simpson JT; Mackie K; Devane WA
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7656-60. PubMed ID: 8395053
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors.
Farquhar-Smith WP; Jaggar SI; Rice AS
Pain; 2002 May; 97(1-2):11-21. PubMed ID: 12031775
[TBL] [Abstract][Full Text] [Related]
9. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues.
Stamer WD; Golightly SF; Hosohata Y; Ryan EP; Porter AC; Varga E; Noecker RJ; Felder CC; Yamamura HI
Eur J Pharmacol; 2001 Nov; 431(3):277-86. PubMed ID: 11730719
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse.
Lay L; Angus JA; Wright CE
Eur J Pharmacol; 2000 Mar; 391(1-2):151-61. PubMed ID: 10720647
[TBL] [Abstract][Full Text] [Related]
12. Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes.
Sagan S; Venance L; Torrens Y; Cordier J; Glowinski J; Giaume C
Eur J Neurosci; 1999 Feb; 11(2):691-9. PubMed ID: 10051770
[TBL] [Abstract][Full Text] [Related]
13. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
McCollum L; Howlett AC; Mukhopadhyay S
J Pharmacol Exp Ther; 2007 Jun; 321(3):930-7. PubMed ID: 17379772
[TBL] [Abstract][Full Text] [Related]
14. Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells.
Valk P; Verbakel S; Vankan Y; Hol S; Mancham S; Ploemacher R; Mayen A; Löwenberg B; Delwel R
Blood; 1997 Aug; 90(4):1448-57. PubMed ID: 9269762
[TBL] [Abstract][Full Text] [Related]
15. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.
De Petrocellis L; Melck D; Palmisano A; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Proc Natl Acad Sci U S A; 1998 Jul; 95(14):8375-80. PubMed ID: 9653194
[TBL] [Abstract][Full Text] [Related]
16. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
[TBL] [Abstract][Full Text] [Related]
17. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
Priller J; Briley EM; Mansouri J; Devane WA; Mackie K; Felder CC
Mol Pharmacol; 1995 Aug; 48(2):288-92. PubMed ID: 7651362
[TBL] [Abstract][Full Text] [Related]
18. Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation.
Bouaboula M; Desnoyer N; Carayon P; Combes T; Casellas P
Mol Pharmacol; 1999 Mar; 55(3):473-80. PubMed ID: 10051530
[TBL] [Abstract][Full Text] [Related]
19. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
Rinaldi-Carmona M; Barth F; Millan J; Derocq JM; Casellas P; Congy C; Oustric D; Sarran M; Bouaboula M; Calandra B; Portier M; Shire D; Brelière JC; Le Fur GL
J Pharmacol Exp Ther; 1998 Feb; 284(2):644-50. PubMed ID: 9454810
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
Járai Z; Wagner JA; Varga K; Lake KD; Compton DR; Martin BR; Zimmer AM; Bonner TI; Buckley NE; Mezey E; Razdan RK; Zimmer A; Kunos G
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14136-41. PubMed ID: 10570211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
